Non-Small Cell Lung Cancer Therapeutics Market to Reach US$ 64.92 Billion by 2033 | Datam Intelligence

Non-Small Cell Lung Cancer Therapeutics market projected to hit US$ 64.92B by 2033, driven by targeted therapy, immunotherapy, and rising lung cancer prevalence

LOS ANGELES, CA, UNITED STATES, November 12, 2025 /EINPresswire.com/ -- Global Non-Small Cell Lung Cancer Therapeutics Market reached US$21.33 billion in 2024 and is expected to reach US$64.92 billion by 2033, growing at a CAGR of 11.7% during the forecast period 2025-2033.

According to DataM Intelligence Comprehensive Report has released its latest report on the "Non-Small Cell Lung Cancer Therapeutics Market Size 2025," providing a detailed analysis of market trends, key growth drivers, competitive landscape, and regional insights. The report includes market size (value and volume), CAGR projections, and emerging opportunities that help businesses identify growth areas and build effective strategies. Backed by data-driven insights and future outlook, this study serves as a valuable resource for companies looking to stay competitive and capitalize on market potential.

Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/non-small-cell-lung-cancer-therapeutics-market

Industry Latest News 2025:

✅ 23 Jun 2025: Datroway (datopotamab deruxtecan) approved in the U.S. for adult patients with locally advanced or metastatic EGFR‑mutated NSCLC who have received prior EGFR‑directed therapy and platinum‑based chemotherapy.

✅ 8 Aug 2025: Zongertinib (Hernexeos, Boehringer Ingelheim) granted accelerated approval by the U.S. FDA for unresectable or metastatic non‑squamous NSCLC with HER2 (ERBB2) tyrosine kinase domain activating mutations and prior systemic therapy.

✅ 18 Aug 2025: Izalontamab Brengitecan (Iza‑Bren) granted Breakthrough Therapy Designation by the U.S. FDA for previously treated advanced EGFR‑mutated NSCLC (EGFR exon 19 deletions or exon 21 L858R).

✅ 2 Jul 2025: Sunvozertinib (Zegfrovy) granted accelerated approval by the U.S. FDA for adult patients with locally advanced or metastatic NSCLC harbouring EGFR exon 20 insertion mutations, after platinum‑based chemotherapy.

✅ 21 Oct 2025: Takeda Pharmaceutical Company announced a global licensing and collaboration agreement with Innovent Biologics to develop two late‑stage oncology medicines (IBI363, IBI343) worldwide outside Greater China; IBI363 is being evaluated in NSCLC and colorectal cancers.

Market Geographical Share:

North America: North America holds the largest share of the NSCLC therapeutics market. The dominance is driven by the presence of advanced healthcare infrastructure, early cancer detection programs, and strong adoption of innovative therapies such as targeted drugs and immune checkpoint inhibitors. The U.S. remains the primary contributor due to high research funding and regulatory support for oncology drugs.

Europe: Europe represents a significant portion of the market, supported by increasing cancer awareness, well-established healthcare systems, and government initiatives for lung cancer screening. Countries such as Germany, France, and the U.K. are leading in NSCLC treatment adoption.

Asia-Pacific: The Asia-Pacific region is experiencing rapid market growth due to the increasing incidence of lung cancer, rising healthcare expenditure, and expanding awareness regarding modern therapeutic options. Countries like China, Japan, and India are key contributors, driven by growing urban populations and access to innovative treatments.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/non-small-cell-lung-cancer-therapeutics-market

Market Drivers:

✅ Rising Lung Cancer Incidence: The increasing prevalence of NSCLC, particularly in older populations and smokers, is a primary driver of market growth worldwide.

✅ Advancements in Targeted and Immunotherapy Treatments: Development of precision medicine, including EGFR inhibitors, ALK inhibitors, and PD-1/PD-L1 checkpoint inhibitors, is enhancing treatment efficacy and patient outcomes.

✅ Early Diagnosis and Screening Programs: Improved diagnostic tools, including liquid biopsies and next-generation sequencing, enable early detection of NSCLC, boosting the adoption of advanced therapeutics.

✅ Supportive Healthcare Policies: Government initiatives, reimbursement schemes, and increased funding for cancer research accelerate access to advanced NSCLC therapies.

✅ Awareness and Patient Education: Rising awareness about lung cancer symptoms and treatment options drives patients to seek timely medical interventions, supporting the demand for effective therapeutics.

✅ Strategic Collaborations and R&D Investments: Collaborations between pharmaceutical companies and research institutes are accelerating the development of novel therapies and expanding market reach globally.

Segments Covered in the Beverage Premix Market:

By Type (Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma, Adenosquamous Carcinoma, Sarcomatoid Carcinoma)

By Treatment (Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy, Laser Therapy, Photodynamic Therapy (PDT), Others)

By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Regional Analysis for Beverage Premix Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now & Get 30% OFF — Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=non-small-cell-lung-cancer-therapeutics-market

Major Key Players: F. Hoffmann-La Roche Ltd, Mylan N.V., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Novartis AG, Bayer AG, Eli Lilly and Company, Merck & Co., Inc., AstraZeneca, Johnson & Johnson Services, Inc.

✅ Mylan N.V.: Listed among the leading companies in the NSCLC therapeutics space according to multiple market reports, signalling it plays a meaningful role in this segment.

✅ Teva Pharmaceutical Industries Ltd.: Also named among key players in NSCLC therapeutics in recent industry analyses, reflecting its involvement in oncology/respiratory‑oncology portfolios.

✅ Pfizer Inc.: Actively advancing NSCLC therapies — for example its drug Lorbrena (lorlatinib) for ALK‑positive NSCLC is expected to become a blockbuster (>$1 billion annual sales).

✅ Novartis AG: A key oncology player in NSCLC (among others) with NSCLC‑relevant therapies (e.g., the ALK inhibitor Ceritinib) and identified as a major company in this market segment.

✅ Bayer AG: Included among the list of major NSCLC‑therapeutics market participants in market reports, indicating strategic involvement in the lung‑cancer therapy area.

✅ Eli Lilly and Company: Also cited among key NSCLC‐therapeutics market players; for example its monoclonal antibody Necitumumab was approved for a squamous NSCLC indication.

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription

Related Reports:
Squamous Non-Small Cell Lung Cancer Therapeutics Market
lung cancer therapeutics market 2025

Kailas Disale
DataM Intelligence 4market Research LLP
+1 877-441-4866
kailas@datamintelligence.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.